ClinicalTrials.gg
CompletedNCT02137993Updated May 14, 2014

Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia

A Phase 4 interventional study of A-prexa and Zyprexa in Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder, sponsored by HK inno.N Corporation. Completed. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-05-14.

Sponsored by HK inno.N Corporation · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.

Enrollment
63rd of 94
64 · median 114
Started
2012
with 1 other
Phase 4
46 of 97
1 open now
Registered
76th of 97
by date

Among the 97 studies testing olanzapine in Schizophrenia, this one is the 63rd largest by enrollment of the 94 interventional ones that give a count, is one of 2 that started in 2012, is one of 46 in phase 4, and was the 76th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olanzapine

Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 20 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies testing olanzapine in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of A-prexa compared to Zyprexa in patients with schizophrenia, schizophreniform disorder and schizoaffective disorder.

03

Conditions studied

  • Schizophrenia
  • Schizophreniform Disorder
  • Schizoaffective Disorder
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 20 years to 65 years
  • Schizophrenia patient with an acute exacerbation
  • Understand the requirement of the study and voluntarily consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Patients who have another psychiatric disorders
  • Patients who have unstable medical conditions
  • Patients who have abnormalities of liver function test (>2.5 fold of upper normal limit), and vital sign at screening visit
  • Uncontrolled diabetic patients (plasma glucose level is more than 126 mg/dl in fasting condition)
  • Patients who have a history of an allergic reaction to olanzapine
  • Patient who have no clinical response to take two or more different atypical anti-psychotics for more than 4 weeks.
  • Patient who take clozapine within 12 weeks before screening visit
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    A-prexa

    A-prexa 5, 10mg

    Drug: Zyprexa

  • Active comparator
    Zyprexa

    Zyprexa 5, 10mg

    Drug: A-prexa

Interventions

  • DrugA-prexa

    A-prexa 5-20 mg for 6 weeks

  • Zyprexa 5-20 mg for 6 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline at 6 week in total PANSS score

    Time frame: 6 week

Secondary outcomes

  1. Change from baseline at 1, 2, 4 and 6 week in total PANSS score.

    Time frame: 6 week

  2. Responder to be decreased of 30% or more in PANSS total score from baseline at 6 week

    Time frame: 6 week

  3. Change from baseline at 6 week in total CGI-S score

    Time frame: 6 week

  4. Responder rate in CGI-I score of 'very much improved', 'much improved' and 'minimally improved'

    Time frame: 6 week

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2014
First posted
May 14, 2014
Start
Mar 2012
Primary completionActual
May 2013
CompletionActual
May 2013
Last update
May 14, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02137993
Responsible party
Sponsor
First posted
May 14, 2014
Start date
Mar 2012
Primary completion
May 2013
Completion
May 2013
Last update
May 14, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion